Are you working in the field of immuno-oncology leveraging mRNA-LNP-based therapeutic approaches? Then you probably already know about the importance of understanding the complex interactions of mRNA-LNPs with different types of immune and non-immune cells such as cancer cells. But do you know the best ways to get that information?
In this short series of webinars, Dr Justyna Rzepecka, principal scientist at CLS, and Dr Frances Acklam, senior scientist at CLS will:
- Summarise the most common challenges associated with discovery of mRNA-LNP drug products
- Introduce different types of immune cells and role they play in cancer
- Discuss how mRNA-LNP technology can be used to boost immune cells to combat cancer
Specializing in immunology, immuno-oncology and inflammation, CLS provides outsourcing solutions. Their scientists can guide you through a range of in vitro immune cell assays necessary to progress your research program. These assays utilise human primary cells to faithfully recapitulate in vivo immune processes and cellular interactions.
presentadores
- Justyna Rzepecka - Senior Scientist, CLS
- Frances Acklam - Senior Scientist, CLS
Más información
Who should attend?
- Scientists and researchers interested in immunotherapy, immunology, novel therapeutic modalities, mRNA-LNP
What will you learn?
- Explore the most common challenges associated with discovery of mRNA-LNP drug products for immunotherapy
- Learn about the different types of immune cells and their function in the context of cancer
- Discover how mRNA-LNPs can be used to train the immune system to seek out and kill cancer cells